Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
What this study shows
Rapamycin fed from 600 days of age extended median and maximal lifespan in both sexes; age at 90% mortality rose 14% in females and 9% in males.
At a glance
| Evidence type | A Animal model Marked A because it is an animal intervention or observation study measuring an organismal outcome (model: Mouse (genetically heterogeneous, 3 sites)); the code names the system studied -- animal work can be rigorous and still not be human data. |
| Study type | 4 - Animal Study |
| Model system | Mouse (genetically heterogeneous, 3 sites) |
| Journal | Nature |
| Year | 2009 |
| Peer reviewed | Yes |
| Record last updated | 2026-10-01 |
| Source | DOI 10.1038/nature08221 · PMID 19587680 · Free full text (PMC2786175) |
Extracted findings
These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.
| Intervention | Rapamycin (late-life feeding) |
| Target | mTOR |
| Model | Mouse (genetically heterogeneous, 3 sites) |
| Effect | Rapamycin fed from 600 days extended median and maximal lifespan in both sexes – first pharmacological lifespan extension in a mammal |
| Dose | Dietary encapsulated rapamycin, initiated at 600 days of age (or 270 days in a separate study), resulting in blood levels of 60-70 ng/ml. |
| Sample size | 1901 mice (38 still alive at analysis date). |
| Effect size | Pooled mean lifespan increased by 9% for males and 13% for females; life expectancy at 600 days increased by 28% for males and 38% for females (p < 0.0001). |
| Limitations | Improved survival among males at UT and UM might reflect pre-treatment nutritional/health differences, not solely rapamycin effects; additional data needed for accurate effect size and maximal longevity for 270-day start. |
In the Atlas
Related topics
Links in the pathway map
- Supports mTORC1 inhibits Longevity
- Supports Rapamycin activates Longevity
Open questions that cite this study
- Cited as supporting evidence for the open question Does the larger rapamycin benefit in female mice survive equal drug exposure, and is it set by hormones or by chromosomes?.
Answers that reference this study
- Discussed in the plain-language answer How is rapamycin dosed in the longevity studies?.
- Discussed in the plain-language answer Does rapamycin extend lifespan in humans?.
More studies on this topic
- Disruption of the insulin/IGF-1 signaling pathway in Caenorhabditis elegans dramatically increases male longevity and enhances reproductive health late in life (2026)
- Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice (2011)
- Intermittent Administration of Rapamycin Extends the Life Span of Female C57BL/6J Mice (2016)
- Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls (2014)
Was this page useful?
Thank you. Your answer was counted anonymously.